The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Hospira, Inc., a Pfizer company, is recalling the above referenced lot of Dobutamine Injection, USP. Pfizer initiated this recall due to confirmed reports of discolored solution from cracked vials. Pfizer has completed a Health Hazard Assessment which concluded that the use of the impacted products has a remote probability of being associated with minor to serious adverse events such as fever, chills, bacteremia or sepsis. The overall potential risk to the patient arising from this issue is considered to be medium.

Product labeling instructions state this drug should be visually inspected for particulate and discoloration prior to administration. The recall of the above referenced lot of Dobutamine Injection, USP is being conducted to the Hospital/Institution level.

To date, Pfizer has not received reports of any adverse events associated with this issue.

PRODUCT: Dobutamine Injection, USP 250 mg/20 mL (12.5 mg/mL)

NDC NUMBER: (CARTON NDC NUMBER) 0409-2344-02
(VIAL NDC NUMBER) 0409-2344-62

LOT NUMBER: KA5023

EXPIRATION DATE: 02/2026